Applicability and validation of different prognostic scores in allogeneic hematopoietic cell transplant (HCT) in the post-transplant cyclophosphamide era
Salas, María Queralt (Hospital Clínic i Provincial de Barcelona)
Rodríguez Lobato, Luis Gerardo (Hospital Clínic i Provincial de Barcelona)
Charry, Paola (Hospital Clínic i Provincial de Barcelona)
Suárez-Lledó, Maria (Hospital Clínic i Provincial de Barcelona)
Pedraza, Alexandra (Hospital Clínic i Provincial de Barcelona)
Solano, María Teresa (Hospital Clínic i Provincial de Barcelona)
Arcarons, Jordi (Hospital Clínic i Provincial de Barcelona)
Cid, Joan (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Lozano, Miquel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona)
Esteve, Jordi (Hospital Clínic i Provincial de Barcelona)
Carreras, Enric (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Fernandez Aviles, Francesc (Hospital Clínic i Provincial de Barcelona)
Martínez, Carmen (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Rovira Tarrats, Montserrat (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)

Date:	2023
Abstract:	We investigated the predictive capacity of six prognostic indices [Karnofsky Performance Status (KPS), Hematopoietic Cell Transplant-Specific Comorbidity Index (HCT-CI), Disease Risk Index (DRI), European Bone Marrow Transplantation (EBMT) and Revised Pre-Transplantation Assessment of Mortality (rPAM) Scores and Endothelial Activation and Stress Index (EASIX)] in 205 adults undergoing post-transplant cyclophosphamide (PTCy)-based allo-HCT. KPS, HCT-CI, DRI and EASIX grouped patients into higher and lower risk strata. KPS and EASIX maintained appropriate discrimination for OS prediction across the first 2 years after allo-HCT [receiver operating characteristic curve (area under the curve (AUC) > 55 %)]. The discriminative capacity of DRI and HCT-CI increased during the post-transplant period, with a peak of prediction at 2 years (AUC of 61. 1 % and 61. 8 %). The maximum rPAM discriminative capacity was at 1 year (1-year AUC of 58. 2 %). The predictive capacity of the EBMT score was not demonstrated. This study validates the discrimination capacity for OS prediction of KPS, HCT-CI, DRI and EASIX in PTCy-based allo-HCT.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Post-transplant cyclophosphamide ; Allogeneic hematopoietic cell ; Transplantation ; Indices ; Validation
Published in:	Hematology, Transfusion and Cell Therapy, 2023 , ISSN 2531-1387

DOI: 10.1016/j.htct.2023.07.008

10 p, 3.0 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Josep Carreras Leukaemia Research Institute
Articles > Research articles
Articles > Published articles